YPP-10 is under clinical development by Yuyu Pharma and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how YPP-10’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

YPP-10 overview

YP-P10 is under development for the treatment of keratoconjunctivitis sicca (dry eye). It is administered through ophthalmic route in the form of solution.

Yuyu Pharma overview

Yuyu Pharma (Yuyu) is a pharmaceutical and biotechnology company that provides healthcare products. The company’s products include prescription, non prescription, quasi drugs and health supplements. Yuyu prescription drugs comprise osteoporosis drugs, brainbone metabolism-hypocalcemia improvement drugs, cerebral and peripheral circulatory disturbance drugs, respiratory organ drugs, hypertension drugs, tromboembolism drugs, and other circulatory system drugs and it also offers antibiotics, hyperlipidemia drugs, pulmonary tuberculosis therapy drugs, migraine drugs, diabetic neuropathy therapy drugs, urinary system drugs, eczematous dermatitis drugs and antibiotics, among others. The company has operations in South Korea and exports across world. Yuyu is headquartered in Jecheon-si, Seoul, Republic of Korea.

For a complete picture of YPP-10’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.